Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 5,045	$ 5,449	$ 10,631	$ 10,783
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	2,033	2,512	4,556	4,887
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,012	$ 2,937	$ 6,075	$ 5,896